Pancreatic and Hepatic Steatosis in Women with Type 2 Diabetes after Pancreatitis: A Retrospective Cross-Sectional Study
, 2, 3, 4, 5, 6
Abstract
Objective: This study aimed to compare the incidence of pancreatic steatosis and hepatic steatosis between patients with/without diabetes suffering from pancreatitis. Materials and methods: 120 patients between the ages of 18 and 65 years who were hospitalized with pancreatitis were included in the study. The patients were divided into 2 groups: patients with diabetes with pancreatitis (n = 60, Group 1) and patients without diabetes with pancreatitis (n = 60, Group 2). Biochemical blood tests of the patients were analyzed. HU attenuation measurement results on pancreatic abdominal computed tomography (CT) were evaluated retrospectively. The pancreatic-hepatic steatosis status of the patients was recorded. All parameters were compared between the 2 groups. Results: The study was conducted on a total of 120 female patients with pancreatitis. The average age of the patients was 52.3 years, the mean body mass index (BMI) was 27.3 kg/m2, the mean HbA1c was 7.4%, and the mean diabetes duration was 4.6 years. The incidence of pancreatic steatosis was found to be statistically significantly higher in Group 1 (p < 0.05). While 35.0% (n = 21) of pancreatic steatosis was detected in Group 2, 56.7% (n = 34) of Group 1 were found to have pancreatic steatosis. The mean Hounsfield unit (HU) attenuation differences in the pancreas, corpus, and tail in Group 1 and Group 2 were determined to be statistically significant. (p = 0.030, 0.25, and 0.18, respectively). In the correlation analysis, a statistically significant and weak relationship was found between HbA1c and tail and pancreas/spleen values (p < 0.05). It was determined that there was a statistically significant and weak relationship between glucose and corpus, tail, pancreas, and pancreas/spleen values (p < 0.05). Conclusions: In our study, pancreatic steatosis was found to be more common in Group 1. However, no significant difference was detected between Group 1 and Group 2 in terms of hepatosteatosis.
Keywords: type 2 diabetespancreatitispancreatosteatosishepatosteatosis
References
- Habtezion A. Inflammation in acute and chronic pancreatitis. Curr Opin Gastroenterol. 2015; 31(5): 395–399.
- Szatmary P, Grammatikopoulos T, Cai W, et al. Acute Pancreatitis: Diagnosis and Treatment. Drugs. 2022; 82(12): 1251–1276.
- Mederos MA, Reber HA, Girgis MD, et al. Acute Pancreatitis: A Review. JAMA. 2021; 325(4): 382–390.
- Ramkissoon R, Gardner TB. Pancreatic steatosis: an update. Curr Opin Gastroenterol. 2019; 35(5): 440–447.
- Engin A. Non-Alcoholic Fatty Liver Disease. Adv Exp Med Biol. 2017; 960: 443–467.
- ElSayed NA, Aleppo G, Aroda VR, et al. 2. Classification and Diagnosis of Diabetes: Standards of Care in Diabetes-2023. Diabetes Care. 2023; 46(Suppl 1): S19–S40.
- Zeb I, Li D, Nasir K, et al. Computed tomography scans in the evaluation of fatty liver disease in a population based study: the multi-ethnic study of atherosclerosis. Acad Radiol. 2012; 19(7): 811–818.
- Paul J, Shihaz AV. Pancreatic steatosis: a new diagnosis and therapeutic challenge in gastroenterology. Arq Gastroenterol. 2020; 57(2): 216–220.
- Ahbab S, Ünsal A, Ataoğlu HE, et al. Prediabetes and Type 2 Diabetes are Independent Risk Factors for Computed Tomography-Estimated Nonalcoholic Fatty Pancreas Disease. Clinics (Sao Paulo). 2019; 74: e1337.
- Wagner R, Jaghutriz BA, Gerst F, et al. Pancreatic Steatosis Associates With Impaired Insulin Secretion in Genetically Predisposed Individuals. J Clin Endocrinol Metab. 2020; 105(11): 3518–3525.
- Tariq H, Nayudu S, Akella S, et al. Non-Alcoholic Fatty Pancreatic Disease: A Review of Literature. Gastroenterology Res. 2016; 9(6): 87–91.
- Wu WC, Wang CY. Association between non-alcoholic fatty pancreatic disease (NAFPD) and the metabolic syndrome: case-control retrospective study. Cardiovasc Diabetol. 2013; 12: 77.
- Koç U, Taydaş O. Evaluation of pancreatic steatosis prevalence and anthropometric measurements using non-contrast computed tomography. Turk J Gastroenterol. 2020; 31(9): 640–648.
- Begovatz P, Koliaki C, Weber K, et al. Pancreatic adipose tissue infiltration, parenchymal steatosis and beta cell function in humans. Diabetologia. 2015; 58(7): 1646–1655.
- Caldart F, de Pretis N, Luchini C, et al. Pancreatic steatosis and metabolic pancreatic disease: a new entity? Intern Emerg Med. 2023; 18(8): 2199–2208.
- Blaho M, Dítě P, Kunovský L, et al. Fatty pancreas disease: clinical impact. Vnitr Lek. 2018; 64(10): 949–952.
- Pinnick KE, Collins SC, Londos C, et al. Pancreatic ectopic fat is characterized by adipocyte infiltration and altered lipid composition. Obesity (Silver Spring). 2008; 16(3): 522–530.
- Pezzilli R, Calculli L. Pancreatic steatosis: Is it related to either obesity or diabetes mellitus? World J Diabetes. 2014; 5(4): 415–419.
- Tushuizen ME, Bunck MC, Pouwels PJ, et al. Pancreatic fat content and beta-cell function in men with and without type 2 diabetes. Diabetes Care. 2007; 30(11): 2916–2921.